ABCB1 and COVID-19: From collating overall evidence for the association of ABCB1 C3435T genetic polymorphism with therapeutic failure of LPV/RTV in HIV infection of AIDS patients and in cardiovascular disease with another class of medication (e.g., clopidogrel), it is therefore hypothesized that “COVID-19 patients treated with LPV/RTV inheriting ABCB1 pharmacogene in general and in particular ABCB1 C3435T genetic polymorphism might be predisposed to either therapeutic failure or toxicity of this antiviral therapy in considerable proportion of patients” as shown graphically in Figure 1.